Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.

Also called NCT01923181

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 632 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01923181
  • EudraCT 2012-004994-16
Main results
  • Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial JAMA, 2017-10-17 DOI, PubMed 29049653, PMC5817971 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Bulgaria, Canada, Denmark, Germany, Israel, Italy, Malaysia, Serbia, South Africa, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01923181. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2014-12-11 (actual). Results posted on 2019-11-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
semaglutide
Intervention (Drug)
oral placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01923181
Content hash
4f29ac34fb264c3736d84cf80fc9f89363fee530730ec1a13204f5fd439449aa